Anti-angiogenesis drugs Lucentis and Eylea have proved game changers in the treatment of wet age-related macular degeneration, but to stave off AMD blindness, patients must submit every four to eight weeks for the rest of their lives to costly, painful, and potentially dangerous injections in the eyeball. Avalanche Biotechnologies Inc. hopes to replace that chronic regimen with just a single therapeutic gene injection that will set what it describes as an ocular protein factory into production that will stave off AMD pathology long term.
